Trial Profile
Phase I study of TAS-116 in combination with Nivolumab in patients with progressive or metastatic solid cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pimitespib (Primary)
- Indications Biliary cancer; Colorectal cancer; Gastric cancer; Leiomyosarcoma; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Sarcoma; Solid tumours
- Focus Adverse reactions
- Acronyms TAS116nivo_study
- 30 Sep 2021 Results assessing safety and efficacy of TAS-116 plus nivolumab for CRC and other solid tumors.published in the Clinical Cancer Research
- 22 Feb 2021 Status changed from active, no longer recruiting to completed.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology